Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

AstraZeneca: Wettbewerb durch Generika!
AstraZeneca: Wettbewerb durch Generika!
Liebe Leser, letzte Woche überschlugen sich die Nachrichten bei AstraZeneca (AZ), denn ganz ähnlich wie überall im Pharmabereich leidet der Konzern unter dem Verlust von Patenten, die für....
Mylan NV kann sich über deutliche Umsatzsteigerung freuen!
Mylan NV kann sich über deutliche Umsatzsteigerung freuen!
Liebe Leser, Mylan hat in den ersten 9 Monaten den Umsatz um 12,5% gesteigert. Beide Sparten wuchsen ebenfalls um 12,5%: die Generika auf 6,7 Mrd $ und die Spezialitäten auf 1,07 Mrd $. Auch in....
Mylan NV kann sich über deutliche Umsatzsteigerung freuen!
Mylan NV kann sich über deutliche Umsatzsteigerung freuen!
Liebe Leser, Mylan hat in den ersten 9 Monaten den Umsatz um 12,5% gesteigert. Beide Sparten wuchsen ebenfalls um 12,5%: die Generika auf 6,7 Mrd $ und die Spezialitäten auf 1,07 Mrd $. Auch in....
AstraZeneca: Wettbewerb mit preisgünstigeren Generika drückt auf die Ergebnisse!
AstraZeneca: Wettbewerb mit preisgünstigeren Generika drückt auf die Ergebnisse!
Liebe Leser, frühere Kassenschlager wie Nexium, Crestor und Seroquel haben ihren Patentschutz verloren und stehen im Wettbewerb mit preisgünstigeren Generika. Das drückt auf die Ergebnisse. In....
AstraZeneca: Wettbewerb mit preisgünstigeren Generika drückt auf die Ergebnisse!
AstraZeneca: Wettbewerb mit preisgünstigeren Generika drückt auf die Ergebnisse!
Liebe Leser, frühere Kassenschlager wie Nexium, Crestor und Seroquel haben ihren Patentschutz verloren und stehen im Wettbewerb mit preisgünstigeren Generika. Das drückt auf die Ergebnisse. In....
GlaxoSmithKline und Alphabet-Tochter gründen Gemeinschaftsfirma
GlaxoSmithKline und Alphabet-Tochter gründen Gemeinschaftsfirma
Liebe Leser, das britische Pharmaunternehmen GlaxoSmithKline (GKS) macht gemeinsame Sache mit einem Tochterunternehmen der Google-Mutter Alphabet. Wie der Gesundheitskonzern erklärte, werde man gemeinsam
GlaxoSmithKline und Alphabet-Tochter gründen Gemeinschaftsfirma
GlaxoSmithKline und Alphabet-Tochter gründen Gemeinschaftsfirma
Liebe Leser, das britische Pharmaunternehmen GlaxoSmithKline (GKS) macht gemeinsame Sache mit einem Tochterunternehmen der Google-Mutter Alphabet. Wie der Gesundheitskonzern erklärte, werde man gemeinsam
Shire und Baxalta: Der große Tag rückt näher
Shire und Baxalta: Der große Tag rückt näher
Lieber Leser, Baxalta hat jüngst Datum für eine außerordentliche Aktionärsversammlung bekannt gegeben. Am 27. Mai sollen die Baxalta-Anleger darüber entscheiden, ob sie das Übernahmeangebot von Shire akzeptieren.
Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript

Image source: The Motley Fool.

Amarin Plc (NASDAQ: AMRN)Q1 2024 Earnings CallMay 01, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Why Amarin Stock Was Rocketing Higher on Wednesday: https://g.foolcdn.com/editorial/images/771713/medical-professionals-conferring-in-a-hospial-corridor.jpg
Why Amarin Stock Was Rocketing Higher on Wednesday

Any one-product company that receives good news about that product will likely attract investors. That was the case Wednesday with Amarin (NASDAQ: AMRN), which received very encouraging news about

Is Viatris a Great Dividend Stock or Just a Value Trap?: https://g.foolcdn.com/editorial/images/768795/a-couple-reviewing-a-document-at-home.jpg
Is Viatris a Great Dividend Stock or Just a Value Trap?

Viatris (NASDAQ: VTRS) is a large and diverse pharmaceutical business that spun off from Pfizer in 2020. The company's medications are in 165 countries and much of its business centers around

Is Viatris a Great Dividend Stock or Just a Value Trap?: https://g.foolcdn.com/editorial/images/768795/a-couple-reviewing-a-document-at-home.jpg
Is Viatris a Great Dividend Stock or Just a Value Trap?

Viatris (NASDAQ: VTRS) is a large and diverse pharmaceutical business that spun off from Pfizer in 2020. The company's medications are in 165 countries and much of its business centers around

Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript

Image source: The Motley Fool.

Amarin Plc (NASDAQ: AMRN)Q4 2023 Earnings CallFeb 29, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Why Amarin Stock Skyrocketed Today: https://g.foolcdn.com/editorial/images/760915/chart-indicating-gains.jpg
Why Amarin Stock Skyrocketed Today

Shares of Amarin (NASDAQ: AMRN) skyrocketed 32.9% on Wednesday after the biopharmaceutical company announced strong preliminary fiscal fourth-quarter results, a new share-repurchase authorization

Amarin Plc (AMRN) Q3 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
Amarin Plc (AMRN) Q3 2023 Earnings Call Transcript

Image source: The Motley Fool.

Amarin Plc (NASDAQ: AMRN)Q3 2023 Earnings CallNov 01, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?: https://g.foolcdn.com/editorial/images/752405/scientist-looks-at-test-tube.jpg
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?

As you may have heard, Novo Nordisk (NYSE: NVO) makes Ozempic, the type 2 diabetes medication sweeping the globe and raking in billions in the process. Where there's a money-printing drug in ascent

Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?: https://g.foolcdn.com/editorial/images/752405/scientist-looks-at-test-tube.jpg
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?

As you may have heard, Novo Nordisk (NYSE: NVO) makes Ozempic, the type 2 diabetes medication sweeping the globe and raking in billions in the process. Where there's a money-printing drug in ascent

Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?: https://g.foolcdn.com/editorial/images/749955/investor-considers-laptop-with-notebook.jpg
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?

On Oct. 1, Viatris (NASDAQ: VTRS) made an announcement that's sure to shake up its fortunes. It's divesting nearly all of its over-the-counter (OTC) medicines, its entire women's healthcare segment

Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?: https://g.foolcdn.com/editorial/images/749955/investor-considers-laptop-with-notebook.jpg
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?

On Oct. 1, Viatris (NASDAQ: VTRS) made an announcement that's sure to shake up its fortunes. It's divesting nearly all of its over-the-counter (OTC) medicines, its entire women's healthcare segment

Could Viatris Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/748876/rich-person-standing-next-to-a-jet-and-convertible.jpg
Could Viatris Stock Help You Become a Millionaire?

If you're investing $25,000 in your stock portfolio, then getting that investment to be worth $1 million over time is no simple task. Odds are, you'll have to wait decades for that investment to

Could Viatris Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/748876/rich-person-standing-next-to-a-jet-and-convertible.jpg
Could Viatris Stock Help You Become a Millionaire?

If you're investing $25,000 in your stock portfolio, then getting that investment to be worth $1 million over time is no simple task. Odds are, you'll have to wait decades for that investment to

Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks: https://g.foolcdn.com/editorial/images/747177/a-couple-counting-money.jpg
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks

Inflation is giving investors more of an incentive to find ways to increase their income. If you have a decent nest egg saved up, you can use it to invest in dividend stocks to improve your

Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks: https://g.foolcdn.com/editorial/images/747177/a-couple-counting-money.jpg
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks

Inflation is giving investors more of an incentive to find ways to increase their income. If you have a decent nest egg saved up, you can use it to invest in dividend stocks to improve your

Viatris Stock: Bear vs. Bull: https://g.foolcdn.com/editorial/images/745483/two-investors-consider-a-laptop.jpg
Viatris Stock: Bear vs. Bull

If you're wondering whether to buy Viatris (NASDAQ: VTRS) stock this fall, it's important to know the arguments for why it might gain value as well as why it's not the best option.

Generic drug

Viatris Stock: Bear vs. Bull: https://g.foolcdn.com/editorial/images/745483/two-investors-consider-a-laptop.jpg
Viatris Stock: Bear vs. Bull

If you're wondering whether to buy Viatris (NASDAQ: VTRS) stock this fall, it's important to know the arguments for why it might gain value as well as why it's not the best option.

Generic drug